Results 11 to 20 of about 16,188 (197)

Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis

open access: yesBMC Gastroenterology, 2023
Background VISION is a randomised, phase 4, open-label, parallel-group, multicentre study conducted in 33 centres in Japan. The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis ...
Ken Haruma   +9 more
doaj   +1 more source

Lichens: might be considered as a source of gastroprotective molecules? [PDF]

open access: yes, 2013
Indexación: Web of Science; ScieloABSTRACT Lichens are symbiotic relationship between fungi and algae or cyanobacteria. Secondary metabolites from lichens are known as lichen substances.
Areche, Carlos   +3 more
core   +2 more sources

Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines. [PDF]

open access: yesPLoS ONE, 2014
Proton pump inhibitors omeprazole and lansoprazole contain chiral sulfur atom and they are administered as a racemate, i.e. equimolar mixture of S- and R-enantiomers.
Aneta Novotna   +5 more
doaj   +1 more source

Steroids in pediatric eosinophilic esophagitis [PDF]

open access: yes, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis [PDF]

open access: yes, 2009
In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for ≤6 years to assess long-term maintenance therapy.
Thomas O. Kovacs   +5 more
core   +1 more source

Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study [PDF]

open access: yes, 2006
OBJECTIVE: In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice.
Bilušić, Marinko   +6 more
core   +1 more source

Prevalence of drug-herb and drug-supplement interactions in older adults : A cross-sectional survey [PDF]

open access: yes, 2018
© British Journal of General PracticeBackground Polypharmacy is common among older adults, with increasing numbers also using prescription drugs with herbal medicinal products (HMPs) and dietary supplements.
Agbabiaka   +19 more
core   +2 more sources

PERBEDAAN SKOR RSI PENDERITA LARYNGOPHARYNGEAL REFLUX YANG MENDAPAT OMEPRZOLE DAN LANSOPRAZOLE

open access: yesJurnal Kedokteran Diponegoro, 2018
Latar Belakang : Laryngopharyngeal Reflux (LPR) adalah hasil aliran balik isi lambung ke laring faring yang menyebabkan cedera mukosa laring dan faring. Reflux Symptom Index (RSI) digunakan sebagai diagnosis dan evaluasi terapi LPR.
Sri Endah Eka Putri   +2 more
doaj   +1 more source

Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT

open access: yesHealth Technology Assessment, 2021
Background: Persistent throat symptoms are commonly attributed to ‘laryngopharyngeal reflux’. Despite a limited evidence base, these symptoms are increasingly being treated in primary care with proton pump inhibitors.
Janet A Wilson   +14 more
doaj   +1 more source

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study [PDF]

open access: yes, 2017
Objective To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use.Design A phase 3, 24-week ...
Ashida Kiyoshi   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy